VISN 22 Drug Monograph Template

This trial followed patients over a 12 month time period. The primary efficacy end point utilized monthly gadolinium-enhanced magnetic resonance imaging during the six-month treatment period to measure the number of newly active brain lesions. Clinical outcomes … ................
................